Skip to main content

Table 1 Clinical and pathologic characteristics of the Clearview Cancer Institute in Huntsville discovery cohort and the Roswell Park Cancer Institute validation cohort

From: TLE3 as a candidate biomarker of response to taxane therapy

  

CCIH

RPCI

  

Number

Percentage

Number

Percentage

Total patients

 

411

100

81

100

Age

< 50 years

117

28

33

41

 

≥ 50 years

294

72

47

58

 

Unknown

0

0

1

1

Tumor size

T0

1

0

1

1

 

T1

207

50

38

47

 

T2

157

38

26

32

 

T3

19

5

10

12

 

T4

11

3

3

4

 

T unknown

16

4

3

4

Lymph node status

N0

234

57

39

48

 

N1

162

39

27

33

 

N2

7

2

5

6

 

N3

0

0

10

12

 

N unknown

8

2

0

0

Stage

I

170

41

25

31

 

II

206

50

36

44

 

III

35

9

19

23

 

Unknown

0

0

1

1

Grade

1

53

13

0

0

 

2

149

36

7

9

 

3

132

32

70

86

 

Unknown

77

19

4

5

ER status

ER+

276

67

0

0

 

ER-

131

32

81

100

 

ER unknown

4

1

0

0

HER2 status

HER2+

62

15

0

0

 

HER2-

333

81

81

100

 

HER2 unknown

16

4

0

0

Recurrence

 

108

26

55

68

Death

 

58

14

12

15

  1. Data include 12 patients from the larger Roswell Park Cancer Institute (RPCI) validation study. See Results section for details. CCIH, Clearview Cancer Institute in Huntsville; ER, estrogen receptor.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us